China 
Africa 
Explore chapters and articles related to this topic
Sympathetic Neurotransmission
Published in Kenneth J. Broadley, Autonomic Pharmacology, 2017
More recently, competitive reversible and short-acting MAO inhibitors have been developed. The effect of these is readily reversed by any procedure that reduces inhibitor concentration. Furthermore, the duration of action will be controlled by its rate of removal by metabolism and elimination because no covalent bond formation is involved. Substrate and inhibitor binding to the enzyme is mutually exclusive and high concentrations of substrate will displace a competitive inhibitor from the enzyme. Examples include brofaromine (CGP 11305A), moclobemide, cimoxatone and toloxatone, which are selective for MAO-A. Ro 19–6327 is a highly potent and reversible selective MAO-B inhibitor (Figure 2.15) (Kyburz 1990).
Central Neurotransmission in the Elderly
Published in Alvaro Macieira-Coelho, Molecular Basis of Aging, 2017
Hervé Attain, Danièle Bentué-Ferrer
Tricyclic substances are nowadays hardly recommended in elderly subjects, even if their effectiveness appears to be the same as in younger adults;33 the least anticholinergic and the least adrenolytic are to be chosen by priority.9 New-generation antidepressants and serotoninergic drugs seem a more logical choice, equals to the new monoamine oxidase inhibitors (MAOIs) such as moclobemide or brofaromine, which are free of the classic side effects of former MAOIs (tyramine effect, blood pressure changes, etc.).33,34 CRF antagonists could constitute choice antidepressants for the elderly, bearing in mind that fluoxetine has such a property.35
Panic Disorder
Published in Stephen M. Stahl, Bret A. Moore, Anxiety Disorders: A Guide for Integrating Psychopharmacology and Psychotherapy, 2013
Meredith E. Charney, M. Alexandra Kredlow, Eric Bui, Naomi M. Simon
No controlled data are available on the efficacy of monoamine oxidase inhibitors (MAOIs) in PD; however, a few studies on reversible inhibitors of monoamine oxidase A (RIMAs) such as moclobemide or brofaromine (both unavailable in the United States) show similar efficacy compared to SSRIs (Tiller, Bouwer, & Behnke, 1997) or TCAs (Krüger & Dahl, 1999).
Therapeutic strategies for social anxiety disorder: where are we now?
Published in Expert Review of Neurotherapeutics, 2019
Antoine Pelissolo, Sandra Abou Kassm, Lauriane Delhay
The first placebo-controlled RCTs in SAD assessed irreversible monoamine oxidase inhibitors (MAOIs), namely phenelzine. Despite evidence of significant efficacy compared to placebo, phenelzine is not recommended as first or second-line treatment due to its adverse effects profile, dietary limitations and potential for toxicity through food and drug interactions [18]. Moclobemide and brofaromine, two reversible inhibitors of monoamine oxidase A, appeared to be only modestly efficacious in the treatment of SAD, and less effective than SSRIs, venlafaxine, and phenelzine [17]. Other antidepressants have been evaluated for the treatment of SAD with insufficient benefit, such as mirtazapine, or mixed and non-convincing results, such as imipramine, clomipramine, nefazodone, and bupropion [15,18,68].